Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics, Inc. (LYRA)
NASDAQ:LYRA
LYRA Stock Chart & Stats
$3.86
>-$0.01(-3.42%)
At close: 4:00 PM EST
$3.86
>-$0.01(-3.42%)
Day’s Range― - ―
52-Week Range$2.84 - $37.50
Previous CloseN/A
Volume832.93K
Average Volume (3M)30.32K
Market Cap
$6.74M
Enterprise Value$20.86M
Total Cash (Recent Filing)$22.05M
Total Debt (Recent Filing)$31.38M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Mar 11, 2026EPS Estimate
-1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding1,774,882
10 Day Avg. Volume23,879
30 Day Avg. Volume30,323
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)57.96
Price to Sales (P/S)438.05
P/FCF Ratio-9.29
Enterprise Value/Market Cap3.09
Enterprise Value/Revenue34.77
Enterprise Value/Gross Profit69.54
Enterprise Value/Ebitda-0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnhancementsThe new Phase 3 study will include enhancements such as open label extension and independent review panels, aimed at improving the study's statistical power and accuracy.
Regulatory ProgressRegulatory feedback from the FDA has set a clear path towards a New Drug Application for chronic rhinosinusitis patients without nasal polyps.
Study Design ImprovementEncouraging elements in the trial design are believed to meaningfully increase the probability of success for the additional study.
Bears Say
Cash NeedsThe company will need to raise cash to fund the study, and topline data is nearly two years away, leading to a Neutral rating.
Clinical Trial ComplicationsThe necessity to remove background saline irrigation and adjust criteria for CT opacification indicates challenges in differentiating between patients with similar symptoms.
Funding ChallengesManagement has indicated that the potential to start the trial is pending additional funding, which could delay progress.
Lyra Therapeutics News
LYRA FAQ
What was Lyra Therapeutics, Inc.’s price range in the past 12 months?
Lyra Therapeutics, Inc. lowest stock price was $2.84 and its highest was $37.50 in the past 12 months.
What is Lyra Therapeutics, Inc.’s market cap?
Lyra Therapeutics, Inc.’s market cap is $6.74M.
When is Lyra Therapeutics, Inc.’s upcoming earnings report date?
Lyra Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 59 days.
How were Lyra Therapeutics, Inc.’s earnings last quarter?
Lyra Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$3.38 earnings per share for the quarter, beating the consensus estimate of -$5.255 by $1.875.
Is Lyra Therapeutics, Inc. overvalued?
According to Wall Street analysts Lyra Therapeutics, Inc.’s price is currently Overvalued.
Does Lyra Therapeutics, Inc. pay dividends?
Lyra Therapeutics, Inc. does not currently pay dividends.
What is Lyra Therapeutics, Inc.’s EPS estimate?
Lyra Therapeutics, Inc.’s EPS estimate is -1.92.
How many shares outstanding does Lyra Therapeutics, Inc. have?
Lyra Therapeutics, Inc. has 1,774,882 shares outstanding.
What happened to Lyra Therapeutics, Inc.’s price movement after its last earnings report?
Lyra Therapeutics, Inc. reported an EPS of -$3.38 in its last earnings report, beating expectations of -$5.255. Following the earnings report the stock price went down -1.546%.
Which hedge fund is a major shareholder of Lyra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
LYRA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Mustang Bio
―
Bolt Biotherapeutics
―
TransCode Therapeutics
―
Silexion Therapeutics
―